TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 5, Issue 196, Pages 196ra98-196ra98
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-08-01
DOI
10.1126/scitranslmed.3005753
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
- (2011) Brian Magnuson et al. BIOCHEMICAL JOURNAL
- BRAF Inhibitors and Melanoma
- (2011) Keith T. Flaherty CANCER JOURNAL
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
- (2011) F Xing et al. ONCOGENE
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Fine-needle biopsy of metastatic melanoma: clinical use and new applications
- (2010) Rajmohan Murali et al. LANCET ONCOLOGY
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Surgery and radiotherapy in the treatment of cutaneous melanoma
- (2009) A. Testori et al. ANNALS OF ONCOLOGY
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- mTOR signaling at a glance
- (2009) M. Laplante et al. JOURNAL OF CELL SCIENCE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started